In a bid to expand the use of new technologies, a new company is using the term biotechnology to describe the process of creating a drug or drug product from scratch.
Trillium, based in the Netherlands, has developed a new way to make drug-delivery drugs.
Trillium is using a technology called “biotechnological synthesis,” or BTS, which is a form of biotechnology that uses proteins that have been transformed into a compound.
This creates a drug-like molecule that is highly toxic to the body and that can be used in a range of applications, including treating cancer, drug-resistant bacteria, and even helping people to live longer.
The company has been in the process to get BTS into the market for years.
Now Trillum is making the process a bit more affordable.
It’s using a crowdfunding platform called IndieGoGo to crowdfund the production of BTS-inspired drugs.
The platform lets anyone get a $1,000 seed grant to create a drug in a matter of days, and then a year later, a $10,000 funding round.
IndieGoGO founder Peter Bensley told Business Insider that this is an incredibly fast way to get a drug onto the market.
He believes the rapid-growing demand for BTS drugs will drive the technology to the forefront of the pharmaceutical industry.
“I think this is going to be the new standard in the drug industry, and I think that is really going to help us get to the point where we can get really cheap treatments in a short period of time,” Bensiele said.
The idea is to create drugs that have no side effects and can be administered on a day-to-day basis.
Trillinum is not the only startup looking to get into the biotechnology space.
Biopharma has already begun to produce biologics using its BioSynthetic Platform, which combines DNA sequencing technology with the synthetic synthesis of enzymes that can make new drugs.
Biotech giant Monsanto is also making a biotechnology drug using BTS technology, according to an article in The Wall Street Journal.
“I have a lot of experience in the biologistics field,” Bursi said.
“We want to bring new drugs to market that are more efficient and less toxic.
We are looking to do things like that, and hopefully one day we can help you with your day- to-day life as well.”
Bensi added that the company is working on a series of BTT products that could be made in large quantities.
He said Trillums new technology could help companies that are already making drugs to produce them in small batches, as well as smaller pharmaceutical companies, to make them for mass distribution.
“It is an interesting opportunity to make new drug therapies that are not just for the individual patient,” Binsley said.
“This technology can be applied to a wide range of products, from the generic drugs to the biologic products, the pharmaceuticals that we are working on right now.”